Viridian Therapeutics Inc. (1S1)
XDUS 
Summary
1S1 Chart
Viridian Therapeutics: The Song Remains The Same
Viridian Therapeutics is targeting thyroid eye disease with late-stage assets, and shares have dropped significantly over the past six months, despite no major negative news. Analyst sentiment remains bullish, with multiple Buy ratings and price targets far above current levels. The company has a couple of milestones upcoming in 2025 and more pivotal once scheduled in 2026 including a likely FDA approval.
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.79 per share a year ago.
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement.
Viridian Therapeutics Inc. Dividends
Viridian Therapeutics Inc. Earnings
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
Viridian Therapeutics Inc. (1S1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Viridian Therapeutics Inc. ever had a stock split?
Viridian Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Stephen F. Mahoney J.D., MBA CEO | XDUS Exchange | US92790C1045 ISIN |
| US Country | 143 Employees | - Last Dividend | 13 Nov 2020 Last Split | 18 Jun 2014 IPO Date |
Overview
Viridian Therapeutics, Inc. is a pioneering biotechnology company focused on the research and development of innovative treatments for serious and rare diseases. Originating in 2010 and based in Waltham, Massachusetts, the company underwent a significant rebranding from its former identity as Miragen Therapeutics, Inc., embracing the new name Viridian Therapeutics, Inc. in January 2021. This strategic move marks its commitment to advancing healthcare solutions and addressing unmet medical needs through its extensive research in monoclonal antibody technologies and other therapeutic approaches.
Products and Services
- VRDN-001:
- VRDN-003:
- VRDN-006:
- VRDN-008:
A cutting-edge monoclonal antibody specifically targeting the insulin-like growth factor-1 receptor (IGF-1R), VRDN-001 is currently in Phase 3 clinical trials for patients with thyroid eye disease (TED). This promising treatment exemplifies the company's focus on delivering breakthrough solutions for debilitating conditions.
As part of Viridian Therapeutic's commitment to innovating within its field, VRDN-003 represents the next generation of IGF-1R humanized monoclonal antibodies. It incorporates advanced half-life extension technology, offering potential for enhanced treatment of TED. By focusing on the specificity and longevity of antibody interaction, VRDN-003 aims to improve patient outcomes significantly.
This preclinical program underscores the company's dedication to extending its reach beyond TED, exploring the potential of its technology in treating autoimmune diseases. VRDN-006 is at the forefront, representing a bold step into uncharted territories of immunology and therapeutic intervention.
Another promising venture into the realm of autoimmune disease treatment, VRDN-008 shares the stage with VRDN-006 in preclinical development. Together, they signify Viridian Therapeutics' broader ambitions to diversify and enrich their portfolio, addressing a range of autoimmune disorders with innovative, targeted solutions.
Contact Information
